Present status of the use of recombinant human TSH in thyroid cancer management

References

• Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447–63
   PubMed Web of Science ®Google Scholar
• Informationszentrum für Standards in der Onkologie. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Chirurgie-Maligne Schilddrüsentumoren. Kurz Inter Leitl 2000; B2:92ff.
   Google Scholar
• Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, et al. German Society of Nuclear Medicine. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Nuklearmedizin 2004; 43: 115–20
   PubMedGoogle Scholar
• Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297–306
   PubMed Web of Science ®Google Scholar
• Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613–9
   PubMed Web of Science ®Google Scholar
• Botella-Carretero JI, Galan JM, Caballero C, Sancho J, Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocrine Rel Cancer 2003; 10: 601–10
   PubMedGoogle Scholar
• Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniel GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II Study). J Clin Endocrinol Metab 1994; 78: 188–96
   PubMed Web of Science ®Google Scholar
• Ladenson PW, Braverman LE, Mazzaferi E, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888–95
   PubMed Web of Science ®Google Scholar
• Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877–85
   PubMed Web of Science ®Google Scholar
• Pacini F, Ladenson PW, Schlumberger M, Driedger A, Kloos RT, Sherman S, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926–32
   PubMed Web of Science ®Google Scholar
• Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schöpper N, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol 2005; 153: 755–63
   PubMedGoogle Scholar
• Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, et al. Health-related quality of life, depression and anxiety in thyroid cancer patients. Qual Life Res 2006; 15: 695–703
   PubMed Web of Science ®Google Scholar
• Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969; 150: 255–66
   Google Scholar
• McNair DM, Lorr M, Droppeleman LF. EITS manual for the profile of mood states. Educational and Industrial Testing Service; San Diego, CAUSA: 1971.
   Google Scholar
• Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: A 130-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison with recombinant thyrotropin administration. Thyroid 2005; 15: 1147–55
   PubMed Web of Science ®Google Scholar
• Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger MS, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91: 878–84
   PubMed Web of Science ®Google Scholar
• Cohen O, Dabhi S, Karasik A, Zila Zwas S. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocinol 2004; 150: 285–90
   PubMedGoogle Scholar
• Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine I-131 and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997; 82: 11–4
   PubMed Web of Science ®Google Scholar
• Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: Preliminary therapeutic experience. J Endocrinol Invest 1999; 22(Suppl)30–4
   PubMedGoogle Scholar
• Luster M, Lassmann M, Hänscheid M, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 3640–5
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: Current strategies and future directions [Review]. Thyroid 2000; 10: 767–78
   PubMedGoogle Scholar
• Pellegritti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001; 11: 1025–30
   PubMedGoogle Scholar
• Berg G, Lindstedt G, Suurküla M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone (rhTSH). J Endocrinol Invest 2002; 25: 44–52
   PubMed Web of Science ®Google Scholar
• Goffman T, Ioffe V, Tuttle M, Bowers JT, Mason ME. Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma [case history]. Thyroid 2003; 13: 827–30
   PubMedGoogle Scholar
• Menzel C, Kranert WT, Döbert N, Diehl M, Fietz T, Hamscho N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half–life of 131I. J Nucl Med 2003; 44: 1065–8
   PubMed Web of Science ®Google Scholar
• Kovatcheva RD, Hadjieva TD, Kirilov GG, Lozanov BS. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nucl Med Rev 2004; 7: 13–9
   PubMedGoogle Scholar
• Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999; 84: 3867–71
   PubMed Web of Science ®Google Scholar
• Jarzab B, Handkiewicz-Junak D, Gawkowska-Suwinska M. Recombinant human TSH in the diagnosis and treatment of disseminated differentiated thyroid cancer. Nucl Med Rev 2000; 3: 83–8
   PubMedGoogle Scholar
• Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001; 11: 865–9
   PubMed Web of Science ®Google Scholar
• Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid cancer: Single-center study of 54 patients. Eur J Nucl Med Mol Imaging 2003; 30: 1077–86
   PubMed Web of Science ®Google Scholar
• Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, et al. Radioiodine treatment of differentiated thyroid cancer on l-thyroxine plus recombinant human TSH (rhTSH): Initial single-center experience. Eur J Endocrinol 2001; 144: 5–11
   PubMed Web of Science ®Google Scholar
• Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration [clinical case seminar]. J Clin Endocrinol Metab 2001; 86: 5148–51
   PubMed Web of Science ®Google Scholar
• Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Practice 1998; 4: 282–6
   PubMedGoogle Scholar
• Colleran KM, Burge MR. Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: An indication for recombinant thyrotropin. Thyroid 1999; 9: 1249–52
   PubMed Web of Science ®Google Scholar
• Masiukiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999; 9: 1023–7
   PubMed Web of Science ®Google Scholar
• Luster M, Reinhardt W, Koerber C, Lassmann M, Hänscheid H, Michalowski U, et al. The use of recombinant human TSH in a patient with metastatic follicular cancer and secondary hypothyroidism. J Endocrinol Investig 2000; 23: 473–5
   PubMedGoogle Scholar
• Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000; 85: 237–44
   PubMed Web of Science ®Google Scholar
• Checrallah A, Medlej R, Saade C, Khayat G, Halaby G. Malignant struma ovarii: An unusual presentation [case history]. Thyroid 2001; 11: 889–92
   PubMedGoogle Scholar
• Park S-G, Reynolds JC, Brucker-Davis F, Whatley M, McEllin K, Maxted D, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: Comparison of studies with recombinant human TSH (rhTSH) vs. hypothyroidism. J Nucl Med 1996;37(Suppl): 15P. Abstract 49.
   Google Scholar
• Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47: 648–54
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JWA, Franco Sanchez F, et al. Follow-up and management of differentiated thyroid carcinoma: A European perspective in clinical practice. Eur J Endocrinol 2004; 151: 539–48
   PubMedGoogle Scholar
• Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: A European perspective. Eur J Endocrinol 2004; 50: 105–12
   Google Scholar
• Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619–25
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2004; 88: 1433–41
   Google Scholar
• Pacini F, Schlumberger M, Dralle H., Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocinol 2006; 154: 787–803
   PubMed Web of Science ®Google Scholar
• Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: A comprehensive review. Endocr Rel Cancer 2005; 12: 49–64
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, et al. A retrospective review of the effectiveness of recombinant human TSH as preparation for radioiodine thyroid remnant ablation [brief communication]. J Nucl Med 2002; 43: 1482–8
   PubMed Web of Science ®Google Scholar
• Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, et al. Ablation of thyroid residues with 30 mCi 131I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87: 4063–8
   PubMed Web of Science ®Google Scholar
• Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88: 4110–5
   PubMed Web of Science ®Google Scholar
• deKeizer B, Brans B, Hoekstra A, Zelissen PM, Koppeschaar HP, Lips CJ, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging 2003; 30: 367–73
   PubMedGoogle Scholar
• Löffler M, Weckesser M, Franzius C, Kies P, Schober O. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 2003; 42: 240–3
   PubMedGoogle Scholar
• Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin [clinical case seminar]. J Clin Endocrinol Metab 2004; 89: 585–90
   PubMed Web of Science ®Google Scholar
• Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid cancer lung metastases. Thyroid 2004; 14: 465–7
   PubMed Web of Science ®Google Scholar
• Petrich T, Börner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002; 29: 641–7
   Google Scholar
• Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 91–5
   PubMed Web of Science ®Google Scholar
• Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocr Rel Cancer 2005; 12: 1–32
   PubMedGoogle Scholar
• Iorcansky S, Herzovich V, Qualey RR, Tuttle RM. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6553–5
   PubMedGoogle Scholar
• Hoe FM, Charron M, Moshang T, Jr. Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 2006; 19: 25–30
   PubMedGoogle Scholar
• Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittpaldi MR, Fonderico F, et al. Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocrinol Metab 2003; 88: 1319–22
   PubMed Web of Science ®Google Scholar
• Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, et al. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 4047–50
   PubMedGoogle Scholar
• Anderson GS, Fish S, Nakhoda K, Zhuang H, Alavi A, Mandel SJ. Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: A preliminary report. Clin Nucl Med 2003; 28: 93–6
   PubMedGoogle Scholar
• Taïeb D, Lussato D, Mundler O. Subcutaneous administration of recombinant human thyrotropin as an alternative to thyroid hormone withdrawal in patients with anticoagulated thyroid cancer: Preliminary results. Thyroid 2004; 14: 463–4
   PubMedGoogle Scholar
• Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endcrinol Metab 2002; 87: 4160–5
   PubMedGoogle Scholar
• Thyrogen® product labeling, 25 September, 2005, Genzyme Europe BV, Naarden, The Netherlands.
   Google Scholar
• Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: Case report and review of the literature. Endocr Prac 2000; 6: 460–4
   PubMedGoogle Scholar
• Nijhuis TF, van Weperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijd Nucl Geneeskd 1999; 21: 98–100
   Google Scholar